Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation

NCT00628589 is registered in ClinicalTrials.gov with Alexza Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00628589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00628589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation
Lead sponsor
Alexza Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
May 31, 2008
Enrollment
344 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with schizophrenia and acute agitation